So First, a Group of British Scientists Try the Coronavirus Vaccine for Mice - A group of British scientists believes that they have become the first to begin animal testing of vaccines for the new Coronavirus that has killed more than 1,100 people.
Researchers at Imperial College London say their ultimate goal is to have an effective and safe way to stop the spread of SARS types by the end of the year. Similarly, as quoted by Channel News Asia, Wednesday (02/13/2020).
"Right now, we have just put the vaccine we produce from this bacterium into rats," Imperial College London researcher Paul McKay told AFP in an interview.
"We hope that over the next few weeks, we will be able to determine the response we can see in the mice in their blood, their antibody response to the Coronavirus ."
Researchers at Imperial College London say their ultimate goal is to have an effective and safe way to stop the spread of SARS types by the end of the year. Similarly, as quoted by Channel News Asia, Wednesday (02/13/2020).
"Right now, we have just put the vaccine we produce from this bacterium into rats," Imperial College London researcher Paul McKay told AFP in an interview.
"We hope that over the next few weeks, we will be able to determine the response we can see in the mice in their blood, their antibody response to the Coronavirus ."
 |
| Illustration of measles vaccine injection in children (AFP / Johannes Eisele) |
Scientists around the world are competing to develop ways to eradicate new strains of well-known viruses that have been successfully destroyed in the past.
Britain has now recorded eight cases and was forced to close two branches of the medical center in the southeastern city of Brighton, where at least two staff members tested positive for Corona Virus.
However, the process of finding the right vaccine is tiring and usually takes years in animal testing and clinical trials in humans.
The regulator must then ensure that the vaccine is safe and capable enough to be mass-produced.
Imperial College London hopes that research on the SARS coronavirus that has been carried out since nearly two decades ago can accelerate this healing process.
"We hope to be the first to include this special vaccine in human clinical trials, and that maybe our personal goal," McKay said.
"After phase one of the experiment is completed, which can take several months to complete, it can immediately begin to become a trial of efficacy in people, which will also take several months to complete," McKay said.
"So, maybe by the end of this year, there will be a tested vaccine that is suitable for use in humans."
This group was formed at the 2017 World Economic Forum in Davos to help drug companies and universities, join and eradicate dangerous and preventable diseases.
Imperial College London does not work with any team, and currently partners with CEPI and requires its own funding sources.
His scientists hope that successful animal testing can help secure investments that allow clinical trials to start time between June and August.
McKay said it was unfair to say that various universities and companies competed to be the first to develop vaccines.
"There is so much cross-sharing with all this information. I mean the Chinese people, as soon as the genomes are sorted, they share freely with everyone in the world," he said.
"So, putting it in a competitive sense might not be accurate. I would say that this is a collaborative race."
Britain has now recorded eight cases and was forced to close two branches of the medical center in the southeastern city of Brighton, where at least two staff members tested positive for Corona Virus.
However, the process of finding the right vaccine is tiring and usually takes years in animal testing and clinical trials in humans.
The regulator must then ensure that the vaccine is safe and capable enough to be mass-produced.
Imperial College London hopes that research on the SARS coronavirus that has been carried out since nearly two decades ago can accelerate this healing process.
"We hope to be the first to include this special vaccine in human clinical trials, and that maybe our personal goal," McKay said.
"After phase one of the experiment is completed, which can take several months to complete, it can immediately begin to become a trial of efficacy in people, which will also take several months to complete," McKay said.
"So, maybe by the end of this year, there will be a tested vaccine that is suitable for use in humans."
Collaborative Race
Much of the world's research that is currently researching the new type of Coronavirus is being funded through the Coalition for Innovation Epidemic Preparedness (CEPI).This group was formed at the 2017 World Economic Forum in Davos to help drug companies and universities, join and eradicate dangerous and preventable diseases.
Imperial College London does not work with any team, and currently partners with CEPI and requires its own funding sources.
His scientists hope that successful animal testing can help secure investments that allow clinical trials to start time between June and August.
McKay said it was unfair to say that various universities and companies competed to be the first to develop vaccines.
"There is so much cross-sharing with all this information. I mean the Chinese people, as soon as the genomes are sorted, they share freely with everyone in the world," he said.
"So, putting it in a competitive sense might not be accurate. I would say that this is a collaborative race."
